We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+34.04%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.89B
AUM Growth
+$163M
(+4.4%)
Cap. Flow
+$27.4M
Cap. Flow
% of AUM
0.71%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
43
New
3
Increased
8
Reduced
10
Closed
5
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$83.2M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$31.1M |
| 3 |
Erasca
ERAS
|
+$23M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$19.1M |
| 5 |
Palvella Therapeutics
PVLA
|
+$16.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$70.9M |
| 2 |
Abivax
ABVX
|
+$51M |
| 3 |
RAPT Therapeutics
RAPT
|
+$33.3M |
| 4 |
Revolution Medicines
RVMD
|
+$12.3M |
| 5 |
Travere Therapeutics
TVTX
|
+$9.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Miscellaneous | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$227M
| $25.4M | 0.65% |
4,424,725
| – | – |
2024 Q3
6 quarters
|
|
27
Alkermes
ALKS
$6.73B
| $24.8M | 0.64% |
700,647
| – | – |
2024 Q3
6 quarters
|
|
28
Aclaris Therapeutics
ACRS
$514M
| $18.5M | 0.48% |
+4,925,374
| New | +$16.6M |
2026 Q1
0 quarters
|
|
|
29
Monte Rosa Therapeutics
GLUE
$863M
| $16.4M | 0.42% |
+1,000,000
| New | +$19.1M |
2026 Q1
0 quarters
|
|
30
Immunocore
IMCR
$1.52B
| $14.6M | 0.38% |
484,782
+100,000
| +26% | +$3.24M |
2024 Q2
7 quarters
|
|
31
MannKind Corp
MNKD
$1.03B
| $14.5M | 0.37% |
5,900,000
+1,675,000
| +40% | +$7.47M |
2025 Q4
1 quarter
|
|
32
Valneva
VALN
$560M
| $14.3M | 0.37% |
2,291,666
| – | – |
2025 Q2
3 quarters
|
|
33
Evolus
EOLS
$500M
| $10.8M | 0.28% |
2,630,665
| – | – |
2025 Q2
3 quarters
|
|
34
NewAmsterdam Pharma Warrant
NAMSW
| $10M | 0.26% |
500,333
| – | – |
2022 Q4
13 quarters
|
|
35
Allogene Therapeutics
ALLO
$463M
| $9.26M | 0.24% |
3,796,668
-72,082
| -2% | -$144K |
2024 Q1
8 quarters
|
|
36
Autolus Therapeutics
AUTL
$458M
| $6.14M | 0.16% |
4,447,910
-175,414
| -4% | -$266K |
2022 Q1
16 quarters
|
|
37
iBio
IBIO
$50.3M
| $3.71M | 0.1% |
1,953,467
| – | – |
2025 Q4
1 quarter
|
|
38
Xilio Therapeutics
XLO
$59.4M
| $3.55M | 0.09% |
422,505
-2
| -0% | -$16 |
2025 Q4
1 quarter
|
|
|
39
Abivax
ABVX
$8.06B
| – | – |
-378,300
| Closed | -$51M | – |
|
40
Design Therapeutics
DSGN
$656M
| – | – |
-521,000
| Closed | -$4.89M | – |
|
|
41
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-983,333
| Closed | -$33.3M | – |
|
|
RNAM
42
DELISTED
Avidity Biosciences
RNAM
| – | – |
-983,125
| Closed | -$70.9M | – |
|
|
43
Travere Therapeutics
TVTX
$4.98B
| – | – |
-241,592
| Closed | -$9.23M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q1 2026 Portfolio in Review
As of Q1 2026, Frazier Life Sciences Management held 43 positions worth $3.89B, up 4.4% from $3.72B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Frazier Life Sciences Management's Q1 2026 filing shows 3 new, 8 increased, 10 reduced and 5 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M. The largest sale was Avidity Biosciences, an estimated $70.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q1 2026 buy was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $83.2M increase.
- Frazier Life Sciences Management's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $12.3M.
- Frazier Life Sciences Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $70.9M.
- Frazier Life Sciences Management's ten largest holdings make up 73% of its $3.89B portfolio in Q1 2026.
- Frazier Life Sciences Management opened 3 new positions and closed 5 in Q1 2026.
- Frazier Life Sciences Management's portfolio value rose 4.4% quarter-over-quarter to $3.89B.
Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.